Skip Navigation


JAC Advance Access originally published online on May 2, 2008
Journal of Antimicrobial Chemotherapy 2008 62(2):246-255; doi:10.1093/jac/dkn193
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
62/2/246    most recent
dkn193v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hartzell, J. D.
Right arrow Articles by Weintrob, A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hartzell, J. D.
Right arrow Articles by Weintrob, A. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Reviews

Impact of depression on HIV outcomes in the HAART era

Joshua D. Hartzell1,2,*, Igor E. Janke3 and Amy C. Weintrob1,2

1 Infectious Diseases Service, Department of Medicine, BLD 2, Ward 63, Walter Reed Army Medical Center, 6900 Georgia Avenue NW, WA DC 20307-5001, USA 2 Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814, USA 3 Department of Psychiatry, BLD 2, Ward 63, Walter Reed Army Medical Center, 6900 Georgia Avenue NW, WA DC 20307-5001, USA

* Correspondence address. Infectious Diseases Service, BLD 2, Ward 63, Walter Reed Army Medical Center, 6900 Georgia Avenue NW, WA DC 20307, USA. Tel: +1-202-782-1663; E-mail: Joshua.Hartzell{at}amedd.army.mil

Highly active antiretroviral therapy (HAART) has significantly decreased the morbidity and mortality of persons infected with HIV. The extent of the benefits, however, is not uniform, and certain factors including ethnicity, gender, baseline HIV viral load and CD4+ T lymphocyte count, adherence and intravenous drug abuse are associated with different immunological, virological and clinical outcomes. Mental health illness (MHI) and specifically depression may be associated with worse outcomes, although studies exploring the impact of MHI on HIV outcomes in both the pre-HAART and post-HAART eras have shown mixed results. The objective of the current paper is to review the available literature on the impact of MHI on HIV outcomes in the HAART era.

Keywords: AIDS , mental health , psychiatric


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.